A large randomized trial showed that dual antiangiogenic therapy in previously treated patients with advanced renal cancer significantly improved progression-free survival (PFS) over single-agent therapy. Median PFS improved from 10.7 months with monotherapy. The study was conducted in San Francisco and was featured on MedPage Today. The dual antiangiogenic combination provided a significant benefit compared with a single antiangiogenic drug. The main finding confirms better disease control in patients with an advanced stage.